Basal-cell carcinoma

MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

Retrieved on: 
Thursday, March 21, 2024
Burn, Tax, Debridement, Patient, EWMA, Bank statement, Eschar, Investment, SAWC, Therapy, Depreciation, European Commission, Phase, BCC, Research, Supplement, Wound, EMA, GMP, HERE, Safety, CMS, BLA, Eastern Time Zone, Food, Bromelain (pharmacology), WBP, Development, PMI, WHS, Adjustment, FDA, BMCI, Forecasting, Symposium, Incidence, BSV, Basal-cell carcinoma, Operating cost, European Wound Management Association, Table, Event, Medicare, Pharmaceutical industry

YAVNE, Israel, March 21, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • Revenue: Revenue for the fourth quarter 2023 was $5.3 million, compared to $11.6 million in the fourth quarter of 2022.
  • Research and development expenses in the fourth quarter 2023 were $1.8 million compared to $2.7 million in the fourth quarter of 2022.
  • Selling, general, and administrative expenses in the fourth quarter 2023 were $2.8 million, compared to $3.0 million in the fourth quarter of 2022.
  • Operating Results: Operating loss in the fourth quarter of 2023 was $3.9 million, compared to an operating profit of $2.1 million in the fourth quarter of 2022.

Common Skin Cancer, Like Christie Brinkley’s, Can Often Be Cured Without Surgery

Retrieved on: 
Thursday, March 14, 2024
Skin, Skin cancer, Patient, SRT, Mohs surgery, Dermatology, Cancer, Insurance, Basal-cell carcinoma, Carcinoma, Patent, Pain, Medicare, Marketing, FDA, Food, Medical imaging

Basal cell carcinoma, which Brinkley had, and squamous cell carcinoma are forms of nonmelanoma skin cancer, the most common type of cancer in the United States.

Key Points: 
  • Basal cell carcinoma, which Brinkley had, and squamous cell carcinoma are forms of nonmelanoma skin cancer, the most common type of cancer in the United States.
  • Brinkley had Mohs surgery, the traditional treatment that dates back to the 1930s,” says dermatologist and surgeon Dr. Janine Hopkins of Hopkins Dermatology, Monroe, Louisiana and Southlake, Texas.
  • The treatment is administered over the course of 15-minute sessions, with no cutting, pain, surgical scarring or need for reconstructive surgery.
  • SkinCure Oncology recently announced receipt of a U.S. patent for a new image-guided technology that will be the fourth generation of SRT.

Human medicines European public assessment report (EPAR): Nulojix, belatacept, Date of authorisation: 17/06/2011, Revision: 21, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Urine, Medical Subject Headings, Diarrhea, Awareness, Marketing, Basiliximab, European Commission, INN, Leukopenia, Risk, Post-transplant lymphoproliferative disorder, Kidney transplantation, Infection, MPA, ATC, Pneumonia, Urinary tract infection, International, Gastroenteritis, Cytomegalovirus, Mycophenolic acid, Language, Pyelonephritis, Ciclosporin, CD86, Cancer, Basal-cell carcinoma, Transplant, Select, Committee, Patient, Human, Dehydration, Risk management, Anatomy, Medicine, Anemia, Vomiting, IIA, CHMP, CD80, Rejection, Dentistry

Human medicines European public assessment report (EPAR): Nulojix, belatacept, Date of authorisation: 17/06/2011, Revision: 21, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Nulojix, belatacept, Date of authorisation: 17/06/2011, Revision: 21, Status: Authorised

Inhibitor Therapeutics, Inc. Exclusive License with Johns Hopkins University

Retrieved on: 
Wednesday, December 13, 2023
Licensing factor, Johns Hopkins University, FGF, HUVEC, Inhibitor, JHU, Itraconazole, Basal-cell carcinoma, Therapy, National Cancer Institute, VDAC1, INTI, Literature, Cell proliferation, Patient, BCC, EGF, Angiogenesis inhibitor, Prostate cancer, Endothelium, AMPK, VEGF, Neoplasm, System, License, Blood, Enzyme inhibitor, Cancer, ATP, Lung cancer, Growth, API, Metastasis, Invention, RNA, Patent, Pharmaceutical industry, Vaccine

TAMPA, Fla., Dec. 13, 2023 /PRNewswire/ -- Inhibitor Therapeutics, Inc. ("Inhibitor") (OTCQB: INTI) has entered into an exclusive, worldwide licensing agreement (the "License") with Johns Hopkins University (JHU) for their U.S Patent 8,980,930 (Canada Patent 2,572,223) "New Angiogenesis Inhibitors". Angiogenesis Inhibitors, as described by the National Cancer Institute, are unique cancer fighting agents as they block the growth of blood vessels that support tumor growth rather than blocking the growth of the tumor cells themselves. Inventors affiliated with JHU developed this patent, listing Itraconazole as an Active Pharmaceutical Ingredient (API) that has anti-angiogenic properties.

Key Points: 
  • TAMPA, Fla., Dec. 13, 2023 /PRNewswire/ -- Inhibitor Therapeutics, Inc. ("Inhibitor") (OTCQB: INTI) has entered into an exclusive, worldwide licensing agreement (the "License") with Johns Hopkins University (JHU) for their U.S Patent 8,980,930 (Canada Patent 2,572,223) "New Angiogenesis Inhibitors".
  • Inventors affiliated with JHU developed this patent, listing Itraconazole as an Active Pharmaceutical Ingredient (API) that has anti-angiogenic properties.
  • Inhibitor believes the License is a mutually beneficial agreement, yielding a modest annual royalty rate with milestone payments typical to such a license.
  • A total of 13 new 'surgically eligible' lesions across 8 of the 38 patients developed over the duration of the study.

Latest study demonstrates high efficacy in curing invasive non-melanoma skin cancer

Retrieved on: 
Wednesday, October 25, 2023
Neoplasm, Patient, Cutaneous squamous-cell carcinoma, Incidence, NMSC, Georgetown University Medical Center, BCC, University Medical Center, Head, Face, Basal-cell carcinoma, CSCC, Cryotherapy, Carcinoma, Cancer, Radiation, Ear, Rhenium, Safety, Skin cancer, Hypopigmentation, Nose, Dentistry, Pharmaceutical industry, Veterinary medicine

MUNICH, Oct. 25, 2023 /PRNewswire/ -- Results from a recently completed study show topical rhenium-188 skin cancer therapy to be a highly effective option for treating non-melanoma skin cancer (NMSC) of up to 3 mm thickness.1

Key Points: 
  • Research lead, Professor Tietze from the University Medical Center, Rostock says, "The study found rhenium skin cancer therapy to be a highly effective treatment for NMSCs, in particular, the cosmetic outcomes on the head and face.
  • The study involved 22 patients with 40 histologically confirmed NMSCs (57.5% basal cell carcinomas (BCCs), 12.5% cutaneous squamous cell carcinomas (cSCCs), 30% Bowen's disease lesions).
  • This study shows the efficacy of rhenium skin cancer therapy demonstrating a 97.5% response rate with 37 of the 39 lesions showing complete response at 12 months," adds Professor Tietze.
  • All procedures performed in this study were in accordance with the 1964 Helsinki declaration and its later amendments.

10x Genomics Surpasses 100 Xenium Analyzer Shipments

Retrieved on: 
Tuesday, August 29, 2023
Tissue, Adelaide, University, FISH, Cancer Institute, Rosenbergia xenium, Genomics, Defence Research and Development Laboratory, Bay Adelaide Centre, 10x Genomics, Research, Research fellow, Genetic distance, RNA, Multiple sclerosis, Cell, H&E, Associate, IHC, Chemistry, Colorectal cancer, B cell, Professor, Data analysis, Melanoma, Icahn Genomics Institute, Biology, Basal-cell carcinoma, Growth, SNV, Health, Environment, Rest, MD Anderson Cancer Center, Gene, Disease, Medical imaging, Vaccine

PLEASANTON, Calif., Aug. 29, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that it has shipped more than 100 Xenium Analyzer instruments in the eight months since the platform's launch. The milestone reflects strong customer demand for the Xenium platform, which is increasingly recognized as the best performing system for in situ analysis.

Key Points: 
  • Rapid growth and adoption of Xenium Analyzer demonstrates strength of company's innovation engine, broad commercial reach and operational scale
    PLEASANTON, Calif., Aug. 29, 2023 /PRNewswire/ -- 10x Genomics , Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that it has shipped more than 100 Xenium Analyzer instruments in the eight months since the platform's launch.
  • I firmly believe Xenium has the potential to be one of the most transformative technologies in our industry in decades."
  • With the vast majority of the first 100 Xenium shipments already installed, researchers are using the system to successfully analyze a variety of tissues and sample types, including fresh frozen, FFPE and tissue microarrays, and reveal new insights into health and disease.
  • Also in 2024, 10x Genomics expects to launch an in-line protein assay to combine with the RNA assays on the exact same tissue section.

Skin cancer screening guidelines can seem confusing – three skin cancer researchers explain when to consider getting checked

Retrieved on: 
Friday, August 11, 2023
People, Melanoma, Survivor, Systematic review, Conversation, American Academy of Dermatology, Awareness, Dermis, Bed, Skin, Neoplasm, Survival, Epidermis, Skin cancer, Light, Cancer, Ultraviolet, Immunity, SPF, Moles, Sunscreen, Prognosis, Clothing, Research, American Academy, Inflammation, Basal-cell carcinoma, Tanning, CDC, Death, Incidence, UPF, Population, Patient, UV, Risk, Overdiagnosis, Carcinoma, Korea Disease Control and Prevention Agency, Lip, Observation, Skin Cancer Foundation, Diagnosis, Program, Center, Sun protection, Burns, Immunodeficiency, Health, Metastasis, Medical imaging, Vaccine, Birth control, Dietary supplement, Cosmetics, Leather, Personal protective equipment, Dermatology

And public health messaging around when and how to be screened for skin cancer has become somewhat confusing.

Key Points: 
  • And public health messaging around when and how to be screened for skin cancer has become somewhat confusing.
  • In April 2023, the U.S. Preventive Services Task Force, an independent national panel of science experts, provided updated recommendations on skin cancer screening following a systematic review of existing research.
  • The task force concluded that the evidence does not support annual widespread skin screening of adolescents and adults, but that catching cancers at the earliest stages reduces the risk of death from skin cancer.

How common is skin cancer in the US?

    • Skin cancer affects about 6 million Americans yearly, according to the Centers for Disease Control and Prevention.
    • Basal cell carcinoma and squamous cell carcinoma – collectively known as keratinocyte cancers – account for more than 97% of skin cancer cases, but invasive melanomas cause the most deaths.
    • Unlike normal cells, skin cancer cells grow without constraints, acquiring the ability to invade down into the dermis.

What are the main causes of skin cancer?

    • Both light- and dark-skinned people can get skin cancer, but light-skinned individuals have a greater risk.
    • Those with light skin, light or red hair, or with numerous moles, are more susceptible to skin damage and severe burns by ultraviolet rays.
    • People who use tanning beds are at a higher risk of skin damage and skin cancers.

What is the debate behind screening?

    • The ongoing debate revolves around whether more screening reduces the death toll from melanoma.
    • This increase may be due in part to more emphasis on early detection.
    • More melanomas have been found, particularly those identified at the earliest stage, also known as stage 0 or melanoma in situ.

What did the task force base its new recommendations on?

    • The task force reviewed current and past data on the major types of skin cancers.
    • The expert panel relied in part on the results of a large public skin cancer screening program in Germany.

When should you get a skin exam?

    • Luckily, there are many online guides on detecting suspicious skin lesions.
    • Whenever you have a concern about a spot on your skin, seek medical advice.
    • This includes those who are older or susceptible to getting skin cancers, skin cancer survivors and immunocompromised people like organ transplant recipients.
    • In response, nonprofits like the American Academy of Dermatology, the Skin Cancer Foundation and The Sun Bus provide resources for free exams.

How can you minimize the risk of skin cancer?


    Strategies that limit UV exposure will reduce skin cancer risk. This includes avoiding sunburns by:
    • Apply these products 15-20 minutes before heading out into the sun and reapply every two hours.
    • UV light is most intense between the hours of 10 a.m. to 4 p.m.
    • These measures can keep your skin healthy into your golden years by reducing skin aging and cancer caused by ultraviolet light.
    • Neil Box receives funding from the National Institutes of Health and the American Skin Association.

Verrica Pharmaceuticals Announces Presentation of Lesion Clearance Data from an Ongoing Phase 2 Study of VP-315 for the Treatment of Basal Cell Carcinoma at the American Academy of Dermatology (AAD) 2023 Innovation Academy Meeting

Retrieved on: 
Thursday, August 10, 2023
Therapy, WEST, Phase II, Dermatology, American Academy, Part, Patient, Biopsy, AAD, Immune system, Part Two, Basal-cell carcinoma, Neoplasm, Principal, Carcinoma, BCC, Skin, Pharmaceutical industry, Vaccine

WEST CHESTER, Pa., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the presentation of lesion clearance data from Part 1 of an ongoing Phase 2 study of VP-315 for the treatment of basal cell carcinoma (BCC). The presentation is titled “VP-315, an Investigational Non-surgical Immunotherapy in Subjects with Biopsy Proven Basal Cell Carcinoma” and highlights the antitumor response of VP-315 as determined by clinical and histological clearance of treated BCC lesions. Dr. Neal Bhatia MD, Director of Clinical Dermatology Therapeutics Clinical Research in San Diego and Principal Investigator for the study, presented the data at the 2023 American Academy of Dermatology Innovation Academy, which is being held from August 10-13th, in Tampa, FL.

Key Points: 
  • The presentation is titled “VP-315, an Investigational Non-surgical Immunotherapy in Subjects with Biopsy Proven Basal Cell Carcinoma” and highlights the antitumor response of VP-315 as determined by clinical and histological clearance of treated BCC lesions.
  • Dr. Neal Bhatia MD, Director of Clinical Dermatology Therapeutics Clinical Research in San Diego and Principal Investigator for the study, presented the data at the 2023 American Academy of Dermatology Innovation Academy, which is being held from August 10-13th, in Tampa, FL.
  • The other 2 subjects showed a partial response in tumor burden reduction (95% tumor clearance and 30% tumor clearance).
  • “We are pleased to report these encouraging results for our novel oncolytic peptide therapy, VP-315, in basal cell carcinoma at this year’s American Academy of Dermatology Innovation Academy,” said Ted White, President and Chief Executive Officer of Verrica Pharmaceuticals.

MediWound Announces Positive Results in Its U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma

Retrieved on: 
Monday, July 10, 2023
University, Lanson-BCC, Basal-cell carcinoma, University of Miami, Trial of the century, Patient, Phase, Concentrate, BCC, Safety, Pharmaceutical industry, Medical device

YAVNE, Israel, July 10, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced positive data from its Phase I/II study to evaluate the safety and efficacy of MW005 in the treatment of low-risk Basal Cell Carcinoma (BCC). The data show MW005 to be safe and well-tolerated, with patients achieving complete clinical and histological clearance of their target lesions.

Key Points: 
  • The data show MW005 to be safe and well-tolerated, with patients achieving complete clinical and histological clearance of their target lesions.
  • The Phase I/II study is an open-label, multi-centered, randomized clinical trial designed to evaluate the safety and efficacy of MW005 in patients with BCC.
  • All of the patients enrolled in the study had histologically confirmed superficial or nodular BCC.
  • Enrolled patients received seven topical applications of MW005 once every other day for fourteen days.

DermaSensor’s Non-Invasive Skin Cancer Device Found to Halve the Number of Skin Cancers Not Referred by PCPs

Retrieved on: 
Thursday, May 4, 2023
Technology, Medical Devices, General Health, Hospitals, Science, Medical Supplies, Clinical Trials, FDA, Biotechnology, Health, Other Science, Research, Other Technology, Other Health, Hardware, Practice Management, Oncology, Melanoma, Basal-cell carcinoma, Carcinoma, ESS, Skin cancer, Mayo Clinic, University of Connecticut School of Medicine, University, Patient, PCP, Skin, Medical imaging

Of the two studies presented, one demonstrated the standalone performance of the hand-held, non-invasive device, and the other evaluated the impact of the device on PCPs’ management of skin cancer.

Key Points: 
  • Of the two studies presented, one demonstrated the standalone performance of the hand-held, non-invasive device, and the other evaluated the impact of the device on PCPs’ management of skin cancer.
  • The ESS device achieved device sensitivity superior to that of the PCPs (95.5% vs. 83.0%, p-value
  • When unaided by the device the PCPs only correctly referred 82.0% of cancerous lesions, whereas when the PCPs were equipped with the device result they correctly referred 91.4% of skin cancers.
  • "As skin cancer rates continue to rise, the need for accurate and efficient skin cancer detection in primary care is increasingly important.